News Archive

Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, and Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, announced today that Mymetics SA, the Swiss subsidiary of Mymetics Corporation and Anergis SA have entered into a Research Collaboration project.

The pre-clinical study program will evaluate the immunogenicity profile of the Anergis peptides designed to treat birch allergy (the Bet v1 COPs) when presented on Mymetics’ proprietary virosomes, with or without undisclosed TLR ligands or other adjuvants, and will compare the results to Anergis’ AllerT product combination (Bet v1 COPs with aluminum hydroxide).

Sunstone Capital today announces that H. Lundbeck A/S (Lundbeck) will acquire Sunstone portfolio company Prexton Therapeutics BV (Prexton).

Prexton develops innovative drugs to improve the quality of life of people who suffer from Parkinson’s disease and other brain disorders. Prexton’s lead compound Foliglurax is currently in clinical phase II for symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (involuntary muscle movements). Prexton is located in Oss (the Netherlands) and Geneva (Switzerland).

Under the terms of the agreement Lundbeck will pay €100 million in cash upfront to Prexton’s current owners and is furthermore required to pay additional €805 million in development, regulatory and sales milestones depending on successful outcome of certain undisclosed milestones.

OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact.

Study OC5-DB-02 (EPHEX) is a randomized, placebo-controlled, 52-week study with the goal to investigate the efficacy and safety of Oxabact in patients with PH. The purpose of the study is to show that Oxabact can halt or delay the disease progression and preserve kidney function.

“This is an important step for OxThera in developing a promising treatment approach for patients suffering from Primary hyperoxaluria, a devastating disease with high unmet medical need. With Oxabact, we are attempting to reduce the systemic oxalate crystal burden and hope to demonstrate that chronic treatment with Oxabact can preserve kidney function for these patients.” said Matthew Gantz, CEO of OxThera.

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing tumor-directed immunotherapies, today announced that the company is scheduled to present at the 10th Annual Biotech Showcase conference held 8-10 January, 2018 in San Francisco, US.

Chief Executive Officer Per Norlén will give an update on the company’s clinical stage project ADC-1013, out-licensed to Janssen Biotech Inc., as well as the near-clinical bispecific antibody ATOR-1015 and the preclinical projects ALG.APV-527 and ATOR-1017.

The presentation will take place on 8 January, at 10:30 a.m. PST /8 Jan 7:30 p.m. CET. The audio and slide presentation will be webcasted live and can be accessed via the Alligator web site. To access the presentation, live and replay, please go to https://event.webcasts.com/starthere.jsp?ei=1175723&tp_key=101995f0f8.

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that a development milestone payment of USD 6 million has been triggered under the partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech, Inc.

The milestone payment is for the partnership agreement to initiate a clinical combination study of ADC-1013 with one of Janssen’s proprietary PD-1 inhibitors. This is the first out of a number of pre-defined milestones, related to the start of combination or phase II studies as part of the ADC-1013 clinical program, which all together have an aggregated potential value of 35 MUSD.

The licensing agreement with Janssen Biotech Inc. encompasses milestone payments up to a potential total value of USD 695 million.  Alligator is also eligible to receive tiered royalties on worldwide net sales upon successful launch and commercialization of ADC-1013.

“We are pleased that our collaboration with Janssen is continuing to progress according to plan”, said Per Norlén, CEO at Alligator Bioscience. “The upcoming combination is a very important step in the continued clinical development. Synergy between ADC-1013 and PD-1 blocking antibodies is supported by pre-clinical data. If this translates to the clinic, it could create new treatment opportunities for many cancer patients”.

Alligator’s partner Janssen Biotech, Inc. is performing a phase I dose-escalation clinical study (ClinicalTrials: NCT02829099) with intravenous administration of JNJ-64457107 (ADC-1013). This study is ongoing with approximately 50 patients recruited to date.